Related Experiment Video
Updated: Sep 17, 2025

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
Location of Terminal Care in Pulmonary Hypertension
Ramzi Ibrahim1, Adam Habib2, April Olson2
1Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA.
Background:
Death locations for individuals in the US is influenced by social factors. Pulmonary hypertension (PH) is an uncommon condition, with a substantial impact on morbidity and mortality. We evaluated the patterns in and impact of demographics on PH death locations in the US.
Methods:
From 2005 to 2020, our study identified PH-related deaths through the CDC repository. Patient-level demographic data for the year 2019 were directly queried from the CDC. Locations of death were categorized into 4 groups, as follows: inpatient; outpatient and/or emergency room (ER); home; and hospice and/or nursing facilities. Linear regression models were used to assess trends in proportion of deaths across these locations. Multivariable logistic regression models examined the influence of demographics on the likelihood of death occurring in each location.
Results:
Between 2005 and 2020, a rise occurred in the proportion of deaths at home (β = 0.006, P < 0.001) and in hospice and/or nursing facilities (β = 0.005, P < 0.001). The odds of dying at home or in hospice and/or nursing facilities increased with age (P < 0.001). Male decedents were more likely than female decedents to die in an outpatient and/or ER setting (odds ratio [OR] 1.22, P = 0.047) and at home (OR 1.16, P = 0.005). Compared to White decedents, Black decedents had higher odds of death in the inpatient (OR 1.99, P < 0.001) and the outpatient and/or ER (OR 1.38, P = 0.007) settings, but lower odds of death at home (OR 0.63, P < 0.001) or in hospice and/or nursing facilities (OR 0.46, P < 0.001).
Conclusions:
Our analysis revealed a significant difference in the locations of death for patients with PH in recent years, as influenced by demographic factors.
More Related Videos
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care